Answers are grounded in this paper and cite their sources.
The FDA has revoked approval of the breast cancer indication for bevacizumab (Avastin; Genetech), saying that studies have not shown enough of a benefit to outweigh the drug's serious and potentially life-threatening side effects.
No takes yet. Share an insight, caveat, or question.
Suzanne J. Rose (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: